



LENALIDOMIDE CIPLA PRESCRIBER REGISTRATION FORM

This is a once-off procedure.

This form needs to be completed by physicians to register on the **Cipla Risk Management Support Programme** before prescribing **LENALIDOMIDE CIPLA** to patients. **Please complete in block letters.**

Prescriber Details

Name & Surname:		Speciality:	
Practitioner Registration Number:			
Address 1:			
Hospital/Centre:			
Street Address:			
Email Address:			
Telephone:		Fax:	
Address 2:			
Hospital/Centre:			
Street Address:			
Email Address:			
Telephone:		Fax:	

I, Dr. _____ [Initials and Surname], have read and understood the **Cipla Risk Management Support Programme Healthcare Professional Information Brochure**. This brochure explains the risks to patients receiving **LENALIDOMIDE CIPLA**, particularly the teratogenic effect on a foetus.

I agree to implement the following **Cipla Risk Management Support Programme** procedures when dealing with these prescriptions:

1.	Provide patient counselling on the potential benefits and risks of LENALIDOMIDE CIPLA treatment and provide the Cipla Risk Management Support Programme Patient Information Brochure to the patient.
2.	Complete a Treatment Initiation Form for each new patient.
3.	Provide contraception counselling in addition to scheduled pregnancy testing to female patients of childbearing potential.
4.	Complete a Prescription Authorisation Form for each patient for each prescription.
5.	Prescribe no more than a 4-week supply of LENALIDOMIDE CIPLA if the patient is a female of childbearing potential.
6.	Prescribe no more than a 12-week supply of LENALIDOMIDE CIPLA if the patient is male or female not of childbearing potential.

Please email the completed/signed form to Cipla Medpro (Pty) Ltd before dispensing **LENALIDOMIDE CIPLA**.

e medinfo@cipla.com

Signature: _____

D	D	M	M	Y	Y	Y	Y
---	---	---	---	---	---	---	---